Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies

The purpose of this study is to determine whether radioactive iodine, as compared to anti-thyroid medications, is a risk factor for the development or progression of thyroid-associated ophthalmopathy in patients with hyperthyroidism due to Graves' disease. The other aim of this study is to determine the incidence of the various ophthalmopathy subtypes and the utility of orbital antibodies in the diagnosis, classification and monitoring of patients with thyroid-associated ophthalmopathy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Graves' Ophthalmopathy Autoimmune Diseases Congenital, Hereditary, and Neonatal Diseases and Abnormalities Endocrine System Diseases Exophthalmos Eye Diseases Eye Diseases, Hereditary Genetic Diseases, Inborn Goiter Graves Disease Graves Ophthalmopathy Hyperthyroidism Immune System Diseases Orbital Diseases Thyroid Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Barwon Health - The Geelong Hospital

Geelong, Victoria, 3220, Australia

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Graves' disease diagnosed in the last 3 months, regardless of the presence of ophthalmopathy

Exclusion criteria

Pre-existing eye disease: e.g. orbital surgery, orbital irradiation or significant loss of vision
Age < 18 years
Inability to consent to participation in the study
Pregnancy
History of radio-active iodine therapy

Treatment and study plan

Carbimazole, radio-active iodine (I131)

Drug

Primary outcomes

Onset or progression of ophthalmopathy following radio-active iodine therapy

Sponsors and collaborators

Lead sponsor

Barwon Health

Other Gov

Collaborators

National Health and Medical Research Council, Australia
University of Melbourne

Registry information

Important dates

Study start: 2003
Study completion: 2006
First posted: Feb 2, 2007
Registry last updated: Feb 2, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed